Based on initial animal studies, cord blood stem cells are potentially capable of generating new blood vessels.
Medistem Laboratories, Inc. (MDSM), is currently in discussions with several academic institutions for completion of pre-clinical studies. This has the potential to enable an Investigational New Drug filing with the FDA, anticipated in the second half of 2007.
This key research is hoped to benefit the 750,000 people in the U.S. alone that suffer from critical limb ischemia.
Let us hear your thoughts below:
